Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Navarixin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 known ✓ | P25025 | 20/20 | 1.00 |
| ▸ | CXCR1 known ✓ | P25024 | 17/20 | 1.00 |
| ▸ | CCR7 | P32248 | 3/20 | 1.00 |
| ▸ | CCR6 | P51684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Navarixin Anhydrous SCHEMBL12262719 | 1.00 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL184744 | 1.00 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL2024684 | 0.99 | CXCR2 (0.98) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL2024683 | 0.99 | CXCR2 (0.98) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12263105 | 0.90 | CXCR2 (0.81) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12087147 | 0.90 | CXCR2 (0.81) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12574856 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262817 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262770 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262756 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190248876-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | UNIV NEW YORK (US) | 2019-08-15 | — | — | US | claimed |
| US-20250296920-A1 | FORMULATIONS COMPRISING N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDE COMPOUNDS AND USES THEREOF | PFIZER INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-12312344-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240368144-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | PFIZER INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-11932683-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | NEW YORK UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-11708360-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-4140486-A1 | METHODS AND COMPOUNDS FOR THE ALLEVIATION AND/OR PREVENTION OF PAIN | Klareskog, Lars (SE) | 2023-03-01 | — | — | EP | disclosed |
| EP-3316886-B1 | METHODS AND COMPOUNDS FOR THE ALLEVIATION AND/OR PREVENTION OF PAIN | SVENSSON CAMILLA (SE) | 2022-05-18 | — | — | EP | disclosed |
| US-20210206757-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | PFIZER INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-11052065-B2 | Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20070155756-A1 | Treatment of chemokine mediated diseases | SCHERING CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155756-A1 | Treatment of chemokine mediated diseases | SCHERING CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1381590-B1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060205961-A1 | Synthesis of 2-hydroxy-N,N-dimethyl-3-[[2-(1(R)-(5-methyl-2-furany)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide | SCHERING CORPORATION | 2006-09-14 | — | — | US | disclosed |
| US-7071342-B2 | Synthesis of 2-hydroxy-N,N-dimethyl-3-[ [2-[1 (R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]aminobenzamide | SCHERING CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1615903-A2 | SYNTHESIS OF 2-HYDROXY-N,N-DIMETHYL-3- [[ 2-[ 1(R)-(5-METHYL-2-FURANYL)PROPYL] AMINO] -3,4-DIOXO-1-CYCLOBUTEN- 1-YL] AMINO BENZAMIDE | SCHERING CORPORATION (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004094398-A2 | SYNTHESIS OF 2-HYDROXY-N,N-DIMETHYL-3-[[2-[1(R)-(5-METHYL-2-FURANYL)PROPYL]AMINO]-3,4-DIOXO-1-CYCLOBUTEN-1-YL]AMINO]BENZAMIDE | SCHERING CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040209946-A1 | Synthesis of 2-hydroxy-N,N-dimethyl-3-[[2-[1(R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-l]aminobenzamide | SCHERING CORPORATION | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155756-A1 | Treatment of chemokine mediated diseases | CXCR3, ACKR3, CCL11 | CXCR2 6/4885CXCR1 5/4885CCR7 14/4885 |
| US-20040209946-A1 | Synthesis of 2-hydroxy-N,N-dimethyl-3-[[2-[1(R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-l]aminobenzamide | CYP1B1, HTR1B, CYP8B1 | CXCR2 1570/4885CXCR1 1495/4885CCR7 3848/4885 |
| US-20210206757-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | CCR6, CCR1, CCR3 | CXCR2 13/4885CXCR1 16/4885CCR7 19/4885 |
| US-20060205961-A1 | Synthesis of 2-hydroxy-N,N-dimethyl-3-[[2-(1(R)-(5-methyl-2-furany)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide | HTR2B, CYP8B1, HTR1B | CXCR2 1692/4885CXCR1 1552/4885CCR7 3211/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | CXCR2 7/4885CXCR1 3/4885CCR7 15/4885 |
| US-20240368144-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | CCR6, CCR1, CCR3 | CXCR2 13/4885CXCR1 16/4885CCR7 19/4885 |
| US-11708360-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | CCR6, CCR1, CCR3 | CXCR2 13/4885CXCR1 16/4885CCR7 19/4885 |
| US-11052065-B2 | Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist | CD274, PDCD1LG2, PDCD1 | CXCR2 4/4885CXCR1 6/4885CCR7 26/4885 |
| US-11932683-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | CXCR1, CXCR2, CXCR5 | CXCR2 2/4885CXCR1 1/4885CCR7 14/4885 |
| US-12312344-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | CCR6, CCR1, CCR3 | CXCR2 13/4885CXCR1 16/4885CCR7 19/4885 |
| US-20250296920-A1 | FORMULATIONS COMPRISING N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDE COMPOUNDS AND USES THEREOF | CCR6, CXCR2, CXCR6 | CXCR2 2/4885CXCR1 12/4885CCR7 21/4885 |
| US-20190248876-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | CXCR2 2/4885CXCR1 1/4885CCR7 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.